3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Parkinson Disease 4, Autosomal Dominant Lewy Body
13
Breast Neoplasms
5
Prostatic Neoplasms
4
Ovarian Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Neoplasms
3
Neoplasm Metastasis
3
Stomatitis
2
Stomach Neoplasms
2
Leukemia, Myeloid, Acute
2
Fallopian Tube Neoplasms
2
Colorectal Neoplasms
2
Colonic Neoplasms
2
Uterine Cervical Neoplasms
1
Triple Negative Breast Neoplasms
1
Trauma, Nervous System
1
Thromboembolism
1
Small Cell Lung Carcinoma
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Multiple Myeloma
1
Metastatic Non-Squamous Non-Small Cell Lung Cancer
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Lymphoma
1
Lipoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Intracranial Hemorrhages
1
Interventions
Paclitaxel
18
pembrolizumab
16
Cisplatin
16
Fluorouracil
15
Irinotecan
13
tislelizumab
9
Oxaliplatin
8
Nivolumab
8
Docetaxel
8
Leucovorin
6
Capecitabine
5
spartalizumab
4
Levoleucovorin
4
Carboplatin
4
lenvatinib
3
durvalumab
3
Radiotherapy
3
Drug Therapy
3
toripalimab
2
sintilimab
2
regorafenib
2
elgemtumab
2
atezolizumab
2
Itraconazole
2
Injections
2
Gemcitabine
2
Bevacizumab
2
130-nm albumin-bound paclitaxel
2
tremelimumab
1
sitravatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Esophageal Squamous Cell Carcinoma
×
Saline Solution
×
Clear all
NCT04210115
2026-05-13
KEYNOTE 975
Merck Sharp & Dohme LLC
Phase 3
Active not recruiting
703 enrolled